SEC Filing Summary: Lifecore Biomedical, Inc. (LFCR)
Business Context and Reporting Period
This Form 8-K was filed by Lifecore Biomedical, Inc. on November 21, 2024. The report serves as a current disclosure under Regulation FD (Item 7.01) regarding the release of investor presentation materials dated November 21, 2024. The company is incorporated in Delaware and trades on the NASDAQ Global Select Market under the symbol LFCR.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for an attached investor presentation (Exhibit 99.1) rather than a standalone financial report containing audited or unaudited financial statements.
Material Changes
No material changes to financial performance or operations are detailed within the text of this Form 8-K. The primary event reported is the public dissemination of the Investor Presentation.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, and risk factors are contained within the Investor Presentation furnished as Exhibit 99.1. The filing explicitly states that the information in this Item 7.01 and the attached exhibit shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Investor Presentation) for actual financial data, strategic outlook, and management commentary.
- Note that the presentation materials are not legally "filed" under Section 18 of the Exchange Act, which may affect liability standards for the information contained therein.
- Verify the company's current stock trading status on the NASDAQ Global Select Market under symbol LFCR.
- Confirm the identity of the authorized signatory, Ryan D. Lake, Chief Financial Officer.